Splash Beverage partners with Lupvindol to advance CannEpil via FDA veterinary pathway
Reuters2026/08/05 12:31- Splash Beverage Group signed a development and collaboration deal with Lupvindol Biosciences to advance CannEpil via the FDA veterinary drug pathway.
- Program targets companion-animal oncology, chronic pain management, with initial focus on dogs.
- Lupvindol to run scientific development, product work, FDA regulatory strategy, including the INAD process, toward potential conditional approval.
- Splash to fund milestones, lead commercialization strategy, retain ownership of study data, regulatory submissions, new IP, licensing rights.
- Lupvindol to absorb the annual FDA sponsor fee through conditional approval unless sponsorship is transferred.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japanese Yen consolidates near August highs vs USD as hawkish BoJ, Fed bets clash
The 10-year U.S. Treasury yield climbs to 4.8%, erasing the dividend advantage of utility stocks; the sector’s rebound depends on interest rate stabilization rather than technical signals.
As U.S. Treasury yields continue to climb, the American utilities sector is experiencing a significant pullback—a rise in yields not only erodes the relative appeal of the sector’s dividends but also raises financing costs for the most capital-intensive industries within this market.
Euro holds gains above 1.1600 despite robust US jobs data, traders eye ECB rate decision
Crypto prices
More
